Gene Therapy Companies Among Top M&A Targets In 2020
Novo Nordisk And Gilead Tipped To Spend
Zolgensma shows that a gene therapy can be a commercial hit – but there is still plenty to be wary of in this cutting-edge field.
You may also be interested in...
A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.